X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES GLENMARK PHARMA ALKEM LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x - 12.1 - View Chart
P/BV x 7.4 3.2 230.6% View Chart
Dividend Yield % 0.6 0.4 155.7%  

Financials

 ALKEM LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
GLENMARK PHARMA
Mar-17
ALKEM LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589993 160.0%   
Low Rs1,232729 168.9%   
Sales per share (Unadj.) Rs417.5325.5 128.2%  
Earnings per share (Unadj.) Rs56.339.3 143.3%  
Cash flow per share (Unadj.) Rs64.748.7 133.0%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.2 387.7%  
Book value per share (Unadj.) Rs292.9159.2 184.0%  
Shares outstanding (eoy) m119.57282.17 42.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.6 127.7%   
Avg P/E ratio x25.121.9 114.3%  
P/CF ratio (eoy) x21.817.7 123.2%  
Price / Book Value ratio x4.85.4 89.0%  
Dividend payout %22.65.1 443.2%   
Avg Mkt Cap Rs m168,653242,991 69.4%   
No. of employees `000NA13.0 0.0%   
Total wages/salary Rs m9,17116,408 55.9%   
Avg. sales/employee Rs ThNM7,083.9-  
Avg. wages/employee Rs ThNM1,265.4-  
Avg. net profit/employee Rs ThNM855.1-  
INCOME DATA
Net Sales Rs m49,91591,857 54.3%  
Other income Rs m1,645374 440.3%   
Total revenues Rs m51,56192,230 55.9%   
Gross profit Rs m8,48220,367 41.6%  
Depreciation Rs m1,0062,644 38.0%   
Interest Rs m6712,373 28.3%   
Profit before tax Rs m8,45115,724 53.7%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m1,6063,827 42.0%   
Profit after tax Rs m6,73111,088 60.7%  
Gross profit margin %17.022.2 76.6%  
Effective tax rate %19.024.3 78.1%   
Net profit margin %13.512.1 111.7%  
BALANCE SHEET DATA
Current assets Rs m27,06268,746 39.4%   
Current liabilities Rs m15,32427,027 56.7%   
Net working cap to sales %23.545.4 51.8%  
Current ratio x1.82.5 69.4%  
Inventory Days Days6785 78.2%  
Debtors Days Days4196 43.2%  
Net fixed assets Rs m12,61024,132 52.3%   
Share capital Rs m239282 84.7%   
"Free" reserves Rs m34,49044,643 77.3%   
Net worth Rs m35,02744,925 78.0%   
Long term debt Rs m1,21245,363 2.7%   
Total assets Rs m54,387117,639 46.2%  
Interest coverage x13.67.6 178.4%   
Debt to equity ratio x01.0 3.4%  
Sales to assets ratio x0.90.8 117.5%   
Return on assets %13.611.4 118.9%  
Return on equity %19.224.7 77.9%  
Return on capital %24.919.1 129.8%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56356,152 11.7%   
Fx outflow Rs m3,0128,084 37.3%   
Net fx Rs m3,55248,068 7.4%   
CASH FLOW
From Operations Rs m7,2596,574 110.4%  
From Investments Rs m1,864-7,124 -26.2%  
From Financial Activity Rs m-9,2735,432 -170.7%  
Net Cashflow Rs m-1501,992 -7.5%  

Share Holding

Indian Promoters % 66.9 48.3 138.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 6.9 479.7%  
FIIs % 0.0 34.4 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.5 -  
Shareholders   68,381 56,727 120.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   SHASUN PHARMA  WYETH LTD  GSK PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Lower; Energy Stocks Witness Losses(11:30 am)

Share markets in India are presently trading marginally lower. Sectoral indices are trading on a mixed note with stocks in the energy sector and auto sector witnessing maximum selling pressure.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 22, 2018 01:07 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS